These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 18035676)

  • 1. [Molecular carcinogenesis of ovarian carcinoma].
    Diebold J
    Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Origins and molecular pathology of ovarian cancer.
    Bell DA
    Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
    Körner M; Burckhardt E; Mazzucchelli L
    J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
    Schlosshauer PW; Ellenson LH; Soslow RA
    Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis in endometrial cancer.
    Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
    Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathology of epithelial ovarian cancer.
    Christie M; Oehler MK
    J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
    Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J
    Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
    Prat J; D'Angelo E; Espinosa I
    Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
    J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precursors and pathogenesis of ovarian carcinoma.
    Lim D; Oliva E
    Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
    Oliva E; Sarrió D; Brachtel EF; Sánchez-Estévez C; Soslow RA; Moreno-Bueno G; Palacios J
    J Pathol; 2006 Apr; 208(5):708-13. PubMed ID: 16429393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
    McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
    J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. My approach to and thoughts on the typing of ovarian carcinomas.
    McCluggage WG
    J Clin Pathol; 2008 Feb; 61(2):152-63. PubMed ID: 17704261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.